Introduction
The Interferon (IFN) family of cytokines are potent suppressors of neoplastic cell growth (Gresser and Belardelli, 2002; Ikeda et al., 2002) . The greater susceptibility of IFN receptor À/À and STAT1 À/À mice to chemical carcinogenesis highlights their importance in suppressing tumor growth (Shankaran et al., 2001) . Although IFNs are clinically highly effective for several human cancers (Kalvakolanu and Borden, 2002) , their modest effects on other tumors can be augmented by combining with other agents. Retinoids are a group of synthetic and natural metabolites related to vitamin A that promote cell growth arrest and differentiation (Altucci and Gronemeyer, 2001) . RA is used effectively for treating acute promyelocytic leukemias, carrying the PML-RARa translocation (Chomienne et al., 1990) . Despite their efficacy against primary cancers of the skin, head and neck (Altucci and Gronemeyer, 2001) , they are clinically ineffective for treating advanced cancers. This led to the use of the IFN/RA combination for clinical therapy of some tumors (Kalvakolanu, 2004) .
We hypothesized that specific genes associated with retinoid-IFN-induced mortality (GRIM) mediate the anti-tumor effect of IFN/RA and hence employed a genetic technique to isolate them (Kalvakolanu, 2004) . One novel proapototic gene, GRIM-19 (Angell et al., 2000) , was identified earlier. In this study, we employed a yeast two-hybrid screen (Y2H) and identified serine protease HtrA2 as one of its interacting partners. HtrA2 belongs to a family of recently discovered mammalian serine proteases (Suzuki et al., 2001; Hegde et al., 2002; Martins et al., 2002; van Loo et al., 2002) . In mammalian cells, inhibitors of apoptosis proteins (IAP) block caspase activation (Vaux and Silke, 2003) . One such protein, the XIAP, inhibits caspase-9. HtrA2 degrades XIAP to relieve the inhibition of caspases (Hegde et al., 2002; Martins et al., 2002; van Loo et al., 2002) . We show here that IFN/RA enhances HtrA2 and GRIM-19 interactions for augmenting cell death. Furthermore, the viral oncoprotein vIRF1 disrupts these interactions to override GRIM-19-induced apoptosis.
Results

Interaction between GRIM-19 and HtrA2 in mammalian cells
We first examined the validity of Y2H data (Supplementary Figure S1 ) to mammalian cells. The mature HtrA2 protein is produced (Hegde et al., 2002) after removal of a 133 aa long N-terminal mitochondrial localization sequence (MLS) from a longer full-length (FL) protein (458 aa) following its import into the mitochondrion (Figure 1a) . Therefore, we co-transfected expression vectors that can produce the flag (f)-epitope tagged FL and ND133 HtrA2 proteins, and a mycepitope-tagged GRIM-19 protein into MCF-7 cells. Cell lysates were immunoprecipitated (IPed) using mycepitope tag-specific antibodies and then subjected to a Western blot (WB) analysis with f-tag-specific antibodies ( Figure 1c ). Although the FL-HtrA2 protein was expressed in the cells, majority of it was processed into the mature form ( Figure 1b) . As expected, only the mature HtrA2 protein and no signal was detected in the ND133 and empty vector-transfected cells, respectively. Both HtrA2 isoforms bound to GRIM-19 indicating that these interactions occur independently of the MLS of HtrA2. All cells expressed a comparable level of myctagged GRIM-19 protein (Figure 1d) .
To determine if endogenous proteins also interact, MCF-7 cell extracts were IPed using GRIM-19-specific (Figure 1e ) or isotype control antibodies, and the products were subjected to WB analysis with HtrA2-specific antibodies. The GRIM-19 antibody, but not the isotype control, IPed endogenous HtrA2. Conversely, GRIM-19 was coIPed by HtrA2-specific (Figure 1g ), but not normal rabbit IgG. Equivalent amounts of GRIM-19 ( Figure 1f ) and HtrA2 ( Figure 1h ) were present in the inputs. GRIM-19:HtrA2 interactions also occur in non-tumorigenic mammary epithelial cells (Supplementary Figure S2A-C) . These interactions also occur directly in vitro (Supplementary Figure S2D) . IFN/RA enhances GRIM-19:HtrA2 interactions As GRIM-19 was an IFN/RA-regulated cell death activator, we next examined the influence of IFN/RA on GRIM-19:HtrA2 interaction. MCF-7 cells were stimulated with IFN/RA for 24 h and the cell extracts were IPed using GRIM-19-specific antibodies. IFN/RA treatment promoted the binding of GRIM-19 to HtrA2 (Figure 2a and b) . Total protein input was comparable as measured by actin levels (Figure 2c ). To study the influence of individual effectors, cells were stimulated with IFN, RA and IFN/RA, and cell extracts were subjected to IP and WB analyses as described above (Figure 2d ). Although IFN alone promoted GRIM-19 and HtrA2 interactions, only IFN/RA significantly increased them. RA alone did not significantly affect these interactions. Figure 2e shows a WB analysis of the input proteins.
As IFN/RA treatment promotes the interactions between GRIM-19 and HtrA2, we next examined whether such enhancement was due to a rise in the physical levels of these proteins (Figure 3 ). MCF-7 cells were stimulated with IFN, RA and IFN/RA for 24 h; RNA and proteins were extracted and used for NB and WB analyses, respectively (Figure 3a and d) . None of these agents induced the expression of HtrA2. However, as reported earlier (Angell et al., 2000) , IFN/RAinduced GRIM-19 mRNA and protein levels ( Figure  3b and e). These blots were probed with GAPDH Cytokine-induced cell death regulation X Ma et al ( Figure 3c ) and actin antibodies (Figure 3f ) to ensure a comparable loading.
Because IFN/RA induces GRIM-19 protein, we investigated whether these interactions occur due to signalinduced post-translational modification(s) or enhanced expression of GRIM-19. Therefore, we transiently transfected cells with expression vectors for HtrA2 ND133 and GRIM-19 (Figure 3g-j) . After treating the cells with IFN/RA for 2 h, lysates were analysed for protein-protein interactions. Whereas there was no difference in the levels of gene expression (Figure 3g and h) , IFN/RA strongly enhanced the binding of GRIM-19 to HtrA2 (Figure 3i and j) . In a complementary experiment, we transfected GRIM-19 into MCF-7 cells and stimulated with IFN/RA for various time points. Cell lysates were IPed with myc-tag specific antibodies and the products were subjected to WB analysis with HtrA2-specific antibodies ( A mutant. These data show that GRIM-19-induced cell death is dependent on a catalytically active HtrA2. The partial apoptosis induced by GRIM-19 in the presence of the mutant HtrA2 may reflect an HtrA2-independent, GRIM-19 driven death regulatory pathway. These effects are not due to a differential expression of the HtrA2 and GRIM-19 proteins (Figure 5b and c). These data were supported by a direct enhancement of HtrA2 activity by GRIM-19 in vitro (Supplementary Figure S4) .
Enhanced downregulation of XIAP by GRIM-19-HtrA2
Because XIAP inhibits apoptosis (Vaux and Silke, 2003) and HtrA2 degrades it (Hegde et al., 2002; Martins et al., 2002; van Loo et al., 2002) , we examined the effect of IFN/RA on XIAP levels. IFN/RA strongly diminished XIAP (Figure 6a ) but not actin (Figure 6b ) levels in a time-dependent manner. A slight decrease in the actin at later time points could possibly because of the activation of full-blown apoptosis.
We next examined the effect of GRIM-19 on HtrA2-mediated degradation of XIAP. MCF-7 cells were transfected with expression vectors coding for GFPHtrA2 and GFP-HtrA2-S 306 A and GRIM-19. The wildtype and mutant enzymes were expressed as GFP fusion proteins. GFP-positive cells were sorted out and XIAP levels were determined. Although HtrA2 itself caused some XIAP degradation, it was augmented significantly in the presence of GRIM-19 (Figure 6c ). More importantly, GRIM-19 failed to promote XIAP degradation in the presence of HtrA2-S 306 A. Thus, GRIM-19 requires the enzymatic activity of HtrA2 for downregulating XIAP.
Because depletion of XIAP activates caspase-9, we next measured caspase-9 activity. Although caspase-9 activity was increased in the presence of wild-type HtrA2 (Figure 6d) , it was further augmented in the presence of To demonstrate a functional relevance of GRIM-19-HtrA2 in regulating XIAP levels in response to IFN/RA, we checked XIAP levels in cells that expressed antisense GRIM-19 or HtrA2. A normal IFN/RA-induced (24 h) decline of XIAP occurred in cells expressing pTKO1 (Figure 6e and h) , which was significantly (P>0.001) inhibited by antisense GRIM-19. These changes in XIAP levels inversely correlated with those of GRIM-19 (Figure 6f) . A small but significant difference (P>0.05) is seen in the presence of anti-sense GRIM-19. This could be due to the activation of alternate IFN/RA-induced pathways. Similarly, antisense HtrA2 significantly (P>0.001) inhibited IFN/RA-induced degradation of XIAP, unlike the control (Figure 6i and l). These differences correlated well with HtrA2 levels in these samples (Figure 6j ). Thus, IFN/RA-induced collaboration between GRIM-19 and HtrA2 appears to mediate a robust XIAP depletion.
vIRF1 of HHV-8 disrupts GRIM-19-HtrA2 interaction
Recently, we have shown that the HHV-8 oncoprotein vIRF1 binds to GRIM-19 and prevents cell death . Because GRIM-19 promotes HtrA2-dependent cell death, we tested the effect of vIRF1 on HtrA2-GRIM-19 interactions. MCF-7 cells were transfected with a pcDNA3.0 vector expressing the vIRF1 along with pEGFPN1. Following various transfections, GFP þ cells were analysed for protein interactions. In Cytokine-induced cell death regulation X Ma et al the presence of vIRF1, HtrA2-GRIM-19 interactions were inhibited, as revealed by a significant loss of HtrA2 protein in the IP products compared to the control (Figure 7a ). The IFN/RA-induced HtrA2-GRIM-19 interaction was inhibited by vIRF1. The loss of these interactions was not due to a decrease of either GRIM-19 or HtrA2 (Figures 7c and d) . As expected, IFN/RA induced GRIM-19 expression (Figure 7c) . Consistent with the loss HtrA2-GRIM-19 interactions, XIAP levels did not decline in presence of vIRF1, even after IFN/ RA treatment (Figure 7d ). The disruption of HtrA2-GRIM-19 interactions inhibited IFN/RA-induced caspase-9 activity in the presence of vIRF1 (Figure 7f ). Thus, vIRF1 ablates GRIM-19-driven apoptosis by disrupting its association with HtrA2. One interesting question is: how does vIRF1, a nuclear protein, prevent the action of GRIM-19? We employed a cell fractionation strategy to address this. MCF-7 cells were electroporated with a vIRF1 expression vector and treated with IFN/RA for 16 h, before to cell fractionation. Each fraction was subjected to WB analysis with various antibodies (Figure 7g ). vIRF1 was primarily found in the nuclear but not the mitochondrial fraction in control and IFN/RA-treated cells. In IFN/RAtreated cells, a small amount of vIRF1 was found in the cytoplasm, showing that under the conditions of apoptosis vIRF1 leaks into the cytoplasm for preventing apoptosis. The purity of these fractions was demonstrated by WB analyses with marker proteins for each fraction: c-jun (nuclear), actin (cytosolic) and cytochrome c (mitochondrial). The c-Jun protein was exclusively detected in nuclear but not in other fractions. The levels of cytochrome c, in mitochondrial fraction declined, indicating a mitochondrial damage. Lastly, there was no change in the total levels of vIRF1, actin and cytochrome c irrespective of the treatments (Figure 7h ).
Discussion
Previous studies from our laboratory have shown that GRIM-19 was present both in nucleus and cytoplasm (Angell et al., 2000) . GRIM-19 was subsequently identified by another group as a subunit of the mitochondrial nicotinamide adenine dinucleotide phosphate (NADPH):ubiquinone oxidoreductase complex I (Fearnley et al., 2001 ). It was not clear, however, how GRIM-19 promotes apoptosis. Here we have shown that GRIM-19 associates with the mitochondrial protease HtrA2. Recently, a number of studies have shown that HtrA2 degrades XIAP, thereby relieving its inhibitory effect on caspase-9 (Hegde et al., 2002; van Loo et al., 2002; Yang et al., 2003) . HtrA2 is upregulated by p53 in some cells (Jin et al., 2003) . Our report identifies a role for this protease in cytokine-induced cell death responses.
Both GRIM-19 and HtrA2 are located in the mitochondrion (Fearnley et al., 2001; Hegde et al., 2002; van Loo et al., 2002; Yang et al., 2003) and our subcellular fractionation confirmed this. That said, GRIM-19 seems to be present in other cellular compartments such as nucleus and cytoplasm (Supplementary Figure S3 ). Both proteins physically interact with each other in vitro and in vivo, and the MLS of HtrA2 is not required for this. Having said that, HtA2:GRIM-19 interactions are weaker in the steady state, which are markedly enhanced by IFN/RA. Although IFN/RA did not induce HtrA2 levels significantly (Figure 3) , it clearly induces the expression of GRIM-19 protein. It is possible that interactions between GRIM-19 and HtrA2 could simply be due to the de novo expression of GRIM-19. However, experiments using the epitope-tagged proteins and short-term IFN/RA treatments (Figure 3) show that these interactions may be due to some ligand-induced posttranslational modifications. At present, the sites of post-translational modifications and factors modulating this process are unknown.
The physiologic relevance of GRIM-19 and HtrA2 to IFN/RA-induced cell death has been shown using multiple approaches (Figures 4-6) . Downregulation of either protein is suffcient for preventing cell death and a signal-induced degradation of caspase inhibitor, XIAP. Similarly, a catalytically inactive HtrA2 mutant fails to augment cell death and the inactivation of XIAP (Figure 6c) . Lastly, recombinant GRIM-19 can promote the protease activity of HtrA2 in vitro (Supplementary Figure S3) . Thus, GRIM-19 and HtrA2 are mutually dependent on each other for upregulating cell death. However, treatment with higher doses or prolonged exposure to IFN/RA caused cell death in HtrA2-antisense-expressing cells (data not shown), indicating that there could be other HtrA2-independent cell death pathways.
HtrA2-dependent cell death occurs slowly, because the synthesis of GRIM-19 and stimulation of its association are IFN/RA dependent. We have shown earlier that IFN/RA-induced caspase-9 activation does not rely on the cleavage of its prodomain (Angell et al., 2000) . Similar to these observations, others have reported that the cleavage of the prodomain of caspase-9 was not required for its activation (Stennicke et al., 1999) . Thus, a GRIM-19-dependent depletion of XIAP may ensure the optimal activation of caspase-9. The PDZ domain of HtrA2 is critical for regulating its activity (Li et al., 2002) . Our isolation of the c-terminal 133 aa of HtrA2 as a binding partner for GRIM-19 (Supplementary Figure S1) suggests that GRIM-19 associates with the PDZ to promote HtrA2 activity. Two other cellular proteins, WARTS, a tumor suppressor protein (Kuninaka et al., 2005) , and Presenilin (Gupta et al., 2004) , also bind to this domain and promote its protease activity. Thus, the PDZ domain seems to act as an integration point for disparate modulators of HtrA2 activity.
Lastly, we have shown the relevance of these interactions to an oncogenic process using the vIRF1 protein of HHV8. Previously, vIRF1 has been shown to transform oncogenically NIH3T3 cells (Gao et al., 1997) and repress IFN gene expression (Zimring et al., 1998) . Our recent studies have shown that vIRF1 binds to GRIM-19 and inhibits apoptosis . Here, we have shown that vIRF1 disrupts the HtrA2 and GRIM-19 interactions, thereby ablating the IFN/RAinduced anti-XIAP activity (Figure 7) . vIRF1 is not a resident of mitochondrian. However, it seems to leak into cytoplasm during IFN/RA treatment, for preventing XIAP degradation (Figure 7g) . Thus, the vIRF1 protein appears to have evolved for ablating specific cellular innate defense mechanisms that prevent virus replication and cellular transformation.
Materials and methods
Antibodies, plasmids and reagents
Horseradish peroxidase coupled to anti-rabbit or anti-mouse antibodies (Amersham Pharmacia Inc. (GE Healthcare) Piscataway, NJ, USA); human IFN-b ser (Berlex Inc., Richmond, CA, USA), mouse monoclonal antibodies against actin and FLAG epitope (Sigma-Aldrich, St Louis, MO, USA), and myc-epitope (Zymed Laboratories Inc., South San Francisco, CA, USA); rabbit polyclonal antibodies against cyotchrome c (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), XIAP protein (Cell Signaling Technology Inc., Danvers, MA, USA) were employed in these studies. Mouse monoclonal antibodies against GRIM-19 were described earlier (Hu et al., 2002) . Rabbit polyclonal antibodies against vIRF1 (Jayachandra et al., 1999) and HtrA2 (Hegde et al., 2002) are described elsewhere. Flag-tagged wildtype FL HtrA2, ND133 (cloned in pcDNA3.1), GFP-tagged ND133 and its catalytic mutant S 306 A (cloned in the pEGFPN1 vector) were described earlier (Hegde et al., 2002) . pCXN2-mycNeo vector expressing myc-tagged GRIM-19, pTKO1 and pTKO1-GRIM-19 is described elsewhere (Angell et al., 2000) . To generate an expression vector capable of producing an antisense HtrA2, we isolated an B600-bp-long EcoRI and XhoI fragment (representing the 3 0 end of the coding region) and subcloned it into a similarly digested pCXN2-myc-Neo vector. The pcDNA3.0-vIRF1 expression vector was a gift from Margaret Offerman (Zimring et al., 1998) .
Y2H screen, cell death and molecular analyses Y2H screen analyses performed using a commercially available Matchmaker 3 kit (Clontech Laboratories Inc., Mountain View, CA, USA). The FL GRIM-19 was used as a bait for identifying interactors from a human bone marrow library (Zhang et al., 2003) . MCF-7 cells (Angell et al., 2000) and hTERT-HME1, a non-oncogenic human mammary epithelial cell line (Clontech Inc.), were grown as recommended by the manufacturer. NB and WB analyses were performed as described in our earlier publications (Angell et al., 2000) . For all control experiments, nonspecifc IgGs of the same subclass were used. Subcellular fractionation was performed as described (Vander Heiden et al., 1997) . In some cases, cells were treated first with cytochalasin B (20 mM) to remove nuclei as described earlier (Dale et al., 1989) , and the cytoplasts (microscopically B98% pure) were stimulated with IFN/RA before fractionation. Annexin-V detection of apoptosis (Trevigen Inc., Gaithersburg, MD, USA) and caspase-9 assays (Biosource International Inc., Camarillo, CA, USA) were performed using commercial kits (Angell et al., 2000) . In vitro HtrA2 activity was determined as described earlier (Li et al., 2002) . The statistical significance of differences between various samples was determined using Student's t-test.
Abbreviations FL, full length; GFP, green fluorescent protein; GRIM, genes associated with retinoid-IFN-induced mortality; HHV8, human herpesvirus 8; Htr, high-temperature-resistant; IFN, interferon; NB, Northern blot; RA, all-trans retinoic acid; STAT, signal transducing activator of transcription; vIRF1, viral interferon regulatory factor 1; WB, Western blot; XIAP, X-linked inhibitor of apoptosis.
